Vanda Pharms

VNDA NASDAQ
13.57
-0.09
-0.66%
Closed 17:11 07/15 EDT
Open
13.66
Prev Close
13.66
High
13.66
Low
13.38
Volume
288.52K
Avg Vol (3M)
732.51K
52 Week High
33.44
52 Week Low
13.00
% Turnover
0.54%
Market Cap
718.72M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Vanda Pharms VNDA stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Vanda Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ is in clinical development for the treatment of Pediatric Non-24, Jet Lag Disorder and Smith-Magenis Syndrome. It offers Fanapt for the treatment of schizophrenia. Fanapt has potential utility in various other disorders. Tradipitant is a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is in clinical development for the treatment of chronic pruritus in atopic dermatitis. Trichostatin A is a small molecule histone deacetylase (HDAC) inhibitor. AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. AQW051 is indicated for the treatment of central nervous system disorders.
MORE >

Recently

Name
Price
%Change